ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Monday, November 18, 2024

10:30AM-12:30PM: Abstract Number: 2166

Nominal Group Technique to Identify What Adolescents with JIA and Parents of Children with JIA Consider When Making Treatment Change Decisions

Patient Outcomes, Preferences, & Attitudes Poster III

10:30AM-12:30PM: Abstract Number: 2018

Non-adherence to Urate Lowering Therapy in Gout After 5 Years Is Related to Poor Outcomes – Results from the NOR-Gout Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster III

10:30AM-12:30PM: Abstract Number: 1808

Not Only Type-I Interferon Regulated Genes Are Differentially Expressed in Circulating Monocytes from Active Lupus Nephritis Patients

SLE – Etiology & Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 2035

Older Age and Higher Erythrocyte Sedimentation Rate Are Associated with Increased Disease Burden at Diagnosis in a Cohort of IgG4-Related Disease Patients

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 1868

Opioid Prescription Rates in Patients with Radiographic Axial Spondyloarthritis in the US Between 2008-2021: A Joinpoint Regression Analysis

Epidemiology & Public Health Poster III

10:30AM-12:30PM: Abstract Number: 2191

Optimizing Inpatient Kawasaki Disease Care

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 1947

Optimizing Osteoarthritis Care Through Clinical and Community Partnership: Results of an Exploratory Trial

Health Services Research – ACR/ARP Poster III

10:30AM-12:30PM: Abstract Number: 2485

Orbital Pseudotumor in Granulomatosis with Polyangiitis. Interim Analysis of Clinical Outcomes from a European Collaborative Observational Study

Vasculitis – ANCA-Associated Poster III

10:30AM-12:30PM: Abstract Number: 2197

Outcome Measures for the Assessment of Cutaneous and Musculoskeletal Manifestations of Juvenile Systemic Sclerosis: An International Collaborative Scoping Review and Survey of Current Practice

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2187

Outcomes Following Tonsillectomy in Children with Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome

Pediatric Rheumatology – Clinical Poster III

10:30AM-12:30PM: Abstract Number: 2220

Outcomes in Seronegative Rheumatoid Arthritis and Undifferentiated Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2383

Outcomes of Systemic Lupus Erythematosus Hospitalizations: Insights from a Multinational Tertiary Center Experience

SLE – Diagnosis, Manifestations, & Outcomes Poster III

10:30AM-12:30PM: Abstract Number: 2042

Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center

Miscellaneous Rheumatic & Inflammatory Diseases Poster III

10:30AM-12:30PM: Abstract Number: 2002

Pain and Physical Function, but Not Fatigue, Track with Disease Activity in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis

Immunological Complications of Medical Therapy Poster

10:30AM-12:30PM: Abstract Number: 1816

Paracrine WNT Signaling Drives Pro-fibrotic Metabolic Activation of Systemic Sclerosis Macrophages

Systemic Sclerosis & Related Disorders – Basic Science Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].